vTv Therapeutics Inc. (VTVT)
$32.35-$0.45 (-1.37%) Today
Srinivas Akkaraju - DirectorvTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
https://www.vtvtherapeutics.comSEC filings for VTVT on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 6 | 36,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
17 Form 4 filings on record, the earliest from Nov 19, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Grant or award | Non-Qualified Stock Option (right to buy) | 6,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non-Qualified Stock Option (right to buy) | 6,000 | $0.00 | - | |
| Daniel K. Spiegelman - Director | Grant or award | Director stock option (right to buy) | 6,000 | $35.08 | $210K | |
| Srinivas Akkaraju - Director | Grant or award | Director stock option (right to buy) | 6,000 | $35.08 | $210K | |
| Fahed Al-Marzooqi - Director | Grant or award | Director stock option (right to buy) | 6,000 | $35.08 | $210K | |
| Anne M. Phillips - Director | Grant or award | Director stock option (right to buy) | 6,000 | $35.08 | $210K | |
| Michael Stephen Tung - Officer | Grant or award | Employee stock option (right to buy) | 44,969 | $36.92 | $1.66M | |
| Paul J. Sekhri - Officer | Grant or award | Class A Common Stock | 140,000 | $36.92 | $5.17M | |
| Srinivas Akkaraju | Grant or award | Class A Common Stock | 106,000 | $15.27 | $1.62M | |
| Srinivas Akkaraju | Grant or award | Pre-Funded Warrants (Right to Buy) | 877,214 | - | - | |
| Srinivas Akkaraju | Grant or award | Warrant (Right to Buy) | 983,214 | - | - | |
| Srinivas Akkaraju | Grant or award | Pre-Funded Warrants (Right to Buy) | 655,523 | - | - | |
| Srinivas Akkaraju | Grant or award | Warrant to Purchase Class A Common Stock (Right to Buy) | 655,523 | - | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Common Stock | 4,308 | - | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Common Stock | 46,692 | - | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Prefunded Warrants | 217,144 | - | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Prefunded Warrants | 2,353,913 | - | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Common Warrant | 221,452 | - | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Common Warrant | 2,400,605 | - | - | |
| Daniel K. Spiegelman - Director | Grant or award | Director stock option (right to buy) | 4,000 | $16.59 | $66K | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Option (right to buy) | 4,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Grant or award | Non- Qualified Stock Option (right to buy) | 4,000 | $0.00 | - | |
| Srinivas Akkaraju - Director | Grant or award | Director stock option (right to buy) | 4,000 | $16.59 | $66K | |
| Srinivas Akkaraju - Director | Grant or award | Director stock option (right to buy) | 2,250 | $17.22 | $39K | |
| Srinivas Akkaraju - Director | Grant or award | Director stock option (right to buy) | 983 | $17.22 | $17K | |
| Samsara BioCapital GP, LLC | Other | Class A Common Stock | 58,836 | - | - | |
| Samsara BioCapital GP, LLC | Grant or award | Pre- Funded Warrants (Right to Buy) | 58,885 | - | - | |
| Srinivas Akkaraju | Derivative | Class A Common Stock | 58,836 | - | - | |
| Srinivas Akkaraju | Grant or award | Pre- Funded Warrants (Right to Buy) | 58,885 | - | - | |
| Paul J. Sekhri - Officer | Open-market purchase | Class A Common Stock | 1,378 | $16.35 | $23K | |
| Paul J. Sekhri - Officer | Open-market purchase | Class A Common Stock | 1,778 | $16.88 | $30K | |
| Paul J. Sekhri - Officer | Open-market purchase | Class A Common Stock | 1,844 | $16.96 | $31K |
vTv Therapeutics Inc. (VTVT) had 5 insider filings in the last 90 days, with the most recent on 2026-06-29. The full record for VTVT runs to 17 Form 4 filings, the earliest from 2024-11-19. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of VTVT were filed in the last 90 days. 3 purchases are on record for this company.
No insider sales of VTVT were filed in the last 90 days.
This page tracks VTVT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add VTVT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
